Interactions of inhibitors and ionizing radiation

Radiation Oncology

Head of Department:
Prof. Dr. med. Rainer Fietkau

Background

An inhibitor (dabrafenib (green)) binds to the kinase b-Raf(V600E) (blue and light blue)

New drugs for the treatment of malignant diseases are constantly coming onto the market. In most cases it is not known whether these new drugs influence the effect of the radiation on tumor cells or cells of healthy tissue. This can lead to an increased sensitivity of the cells, but also to a reduced effect.

In this research group we are studying the effect of the drugs on primary cell cultures and established cell lines as well as in ex vivo experiments on blood and skin.

Publications on the topic:

Veröffentlichungen

Hecht M, Harrer T, Körber V, Sarpong EO, Moser F, Fiebig N, Schwegler M, Stürzl M, Fietkau R, Distel LV. Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation. Oncol Lett. (2018) 15, 1728-1736. doi: 10.3892/ol.2017.7523.

Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, Gutzmer R, Utikal JS, Goldinger SM, Geier M, Hassel JC, Balermpas P, Kiecker F, Rauschenberg R, Dietrich U, Clemens P, Berking C, Grabenbauer G, Schadendorf D, Grabbe S, Schuler G, Fietkau R, Distel LV, Heinzerling L. Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. Br J Cancer. (2018) 118, 785-792. doi: 10.1038/bjc.2017.489

Stritzelberger J, Distel L, Buslei R, Fietkau R, Putz F. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine. Clin Transl Oncol. (2017) doi: 10.1007/s12094-017-1743-x.

Idelalisib may have the potential to increase radiotherapy side effects (2017) Gryc T, Putz F, Goerig N, Ziegler S, Fietkau R, Distel LV, Schuster B. Radiat Oncol. 12
PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis (2016) Markus Hecht, Maike Büttner-Herold, Katharina Erlenbach-Wünsch, Marlen Haderlein, Roland Croner, Robert Grützmann, Arndt Hartmann, Rainer Fietkau, Luitpold V. Distel; European Journal of Cancer 65 p52-60
Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients (2015) M. Hecht, L. Zimmer, C. Loquai, C. Weishaupt, R. Gutzmer, B. Schuster, S. Gleisner, B. Schulze, S. M. Goldinger, C. Berking, A. Forschner, P. Clemens, G. Grabenbauer, T. Müller-Brenne, J. Bauch, H. T. Eich, S. Grabbe, D. Schadendorf, G. Schuler, P. Keikavoussi, S. Semrau, R. Fietkau, L. V. Distel & L. Heinzerling; Annals of Oncology 26 p1238–1244
NNRTI-based antiretroviral therapy may increase risk of radiation induced side effects in HIV-1-infected patients (2015) Keller Ulrike , Hecht Markus, Harrer Thomas, Harrer Ellen, Schuster Barbara, Fietkau Rainer, Luitpold V. Distel; Radiotherapy and Oncology 116 p323-30

 

To top

 

Working group inhibitors